乳腺癌微血管皮瓣重建中围手术期内分泌治疗对皮瓣并发症的风险
该回顾性单中心研究纳入2010年3月至2020年11月接受DIEP或TMG皮瓣乳房重建的560例患者(656个皮瓣),其中198例(224个皮瓣,35.4%)接受围手术期内分泌治疗。结果显示他莫昔芬和芳香化酶抑制剂与术后微血管事件、皮瓣完全坏死或部分坏死均无显著关联。
要点
- 围手术期内分泌治疗与术后微血管事件无显著关联(p=0.254)。
- DIEP皮瓣与术后微血管并发症风险升高相关(OR 2.36,p=0.004)。
- BMI>30与部分皮瓣坏死风险升高相关(OR 4.2,p<0.001)。
核心结论
- 围手术期内分泌治疗不增加微血管并发症风险,该发现对术前停用内分泌治疗的常见做法提出质疑。
研究设计与样本
- 回顾性识别本机构2010年3月至2020年11月期间接受DIEP或TMG皮瓣微血管乳房重建的所有患者,按围手术期内分泌治疗的类型和使用情况分组比较。
主要发现
- 共纳入560例患者(656个皮瓣),198例(224个皮瓣,35.4%)接受围手术期内分泌治疗,发生50例(8.9%)术后微血管事件。
- 他莫昔芬和芳香化酶抑制剂与术后微血管事件(p=0.254)、皮瓣完全坏死(p=0.702)或部分坏死(p=0.916)均无显著关联。
- 接受DIEP皮瓣的患者术后微血管并发症风险更高(OR 2.36,p=0.004),部分皮瓣坏死风险更高(OR 14.66,p<0.001)。
- BMI>30与部分皮瓣坏死风险升高相关(OR 4.2,p<0.001)。
临床怎么用
- 作者认为围手术期内分泌治疗不增加微血管并发症风险,该发现对术前停用内分泌治疗的常见做法提出质疑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone therapy with selective estrogen modulators (tamoxifen) and aromatase inhibitors is commonly used in the treatment of breast cancer. While the increased risk for thromboembolic events has been known since their early application, the potential risk in microsurgical breast reconstruction is still debated. This study aimed to evaluate the risk for microvascular flap complications in patients with perioperative hormone therapy. METHODS: All patients who underwent microsurgical breast reconstruction with a deep inferior epigastric perforator (DIEP) or transverse myocutaneous gracilis flap at our institution between March 2010 and November 2020 were retrospectively identified in our records. Patients were grouped according to the type and use of perioperative hormone therapy. Flap-related thromboembolic events, flap loss, and revision procedures were compared and analyzed between groups. Risk factors associated with postoperative microsurgical complications were determined. RESULTS: A total of 560 patients (656 flaps) were included in our analysis. One hundred ninety-eight patients (224 flaps) received perioperative hormone therapy (35.4%) and 50 (8.9%) postoperative microsurgical events occurred. Tamoxifen and aromatase inhibitors were not associated with postoperative microsurgical events (p = 0.254), full flap loss (p = 0.702), or partial flap loss (p = 0.916). Patients receiving DIEP flaps had a higher risk for postoperative microsurgical complications (OR 2.36, p = 0.004) and partial flap loss (OR 14.66, p < 0.001). A BMI > 30 was associated with an increased risk for partial flap loss (OR 4.2; p < 0.001) CONCLUSION: This article presents one of the largest single-center datasets for the risks of hormone therapy in microsurgical breast reconstruction. Our results show that perioperative hormone therapy does not increase the risk for microsurgical complications. The findings of our study do challenge the common practice of discontinued hormone therapy before microsurgical breast reconstruction.
引用
- Mahrhofer M, Reichert R, Siegwart LC, et al. Risk of perioperative hormonal breast cancer therapy for microvascular flap complications in breast reconstruction. J Plast Reconstr Aesthet Surg. 2023. PMID: 37487260. doi:10.1016/j.bjps.2023.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。